NVS - Novartis said to have backed away from a deal for Cytokinetics
2024-01-11 12:44:34 ET
More on Cytokinetics
- Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)
- Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten
- Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript
- Cytokinetics plunges amid no deal announcement as JPMorgan conf set to end
- Cytokinetics drops as Novartis CEO says the company is focused on bolt-on deals
For further details see:
Novartis said to have backed away from a deal for Cytokinetics